Clinical Trial Update: Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)

View source ↗

Summary

A study evaluating an antiretroviral-sparing concept using HIV-specific T cell precursors with high proliferative capacity (PHPC) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: Genetic Immunity | Conditions: HIV Infection | Status: COMPLETED